

July 12<sup>th</sup> 2023

## Reviewer 1

The reviewer comments on the general merits of the manuscript for readers in the NAFLD field.

### Minor Point

1. The reviewer comments that drug targets are highlighted in Table 1.
2. Response. We have now included this information.

## Reviewer 2

### Minor comments

1. The reviewer comments on points related to future outlook/implications of the review findings.  
Response. We have now included considerably additional text (in yellow) throughout the review to highlight the significance of immunological alterations.
2. The reviewer comments on including the citation citations Global burden of NAFLD and NASH: trends.  
Response. We have now included this citation.
3. The reviewer comments that lines 398 413 are not adequately explained.  
Response. We have now clarified these points.
4. The reviewer comments on the requirement for a section on biomarkers for performing the diagnosis of NAFLD.  
Response. We have now included a new section (in yellow text) on emerging biomarkers.

Yours sincerely,



Dr Vinood Patel, PhD, FHEA, FRSC  
Reader in Clinical Biochemistry  
Pathway Leader for MSc Clinical Biochemistry

E-mail: [v.b.patel@westminster.ac.uk](mailto:v.b.patel@westminster.ac.uk)

Tel: +44 20 350 64138